confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

_Name of Committee:_ Center for Scientific Review Special Emphasis Panel; Metabolomics Core for the Undiagnosed Diseases Network.

_Date:_ July 14–15, 2015.
_Time:_ 8:00 a.m. to 6:00 p.m.
_Agenda:_ To review and evaluate cooperative agreement applications.
_Place:_ National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

_Contact Person:_ Rolf Jakobi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6187, MSC 7806, Bethesda, MD 20892, 301–496–1718, jakobi@mail.nih.gov.

_Name of Committee:_ Center for Scientific Review Special Emphasis Panel; RFA Panel: Molecular and Cellular Substrates of Complex Brain Disorders.

_Date:_ July 24, 2015.
_Time:_ 8:00 a.m. to 6:00 p.m.
_Agenda:_ To review and evaluate grant applications.
_Place:_ Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015.

_Contact Person:_ Deborah L. Lewis, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4183, MSC 7890, Bethesda, MD 20892, 301–408–9129, lewisdebel@csr.nih.gov.

_Name of Committee:_ Center for Scientific Review Special Emphasis Panel; National Primate Research Centers (P51) Revision Application.

_Date:_ July 27, 2015.
_Time:_ 11:00 a.m. to 12:30 p.m.
_Agenda:_ To review and evaluate grant applications.
_Place:_ National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

_Contact Person:_ Brian D. Schuster, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 30098, MSC 7648, Bethesda, MD 20892, (301) 402–4411, tschuster@csr.nih.gov.

_Name of Committee:_ Center for Scientific Review Special Emphasis Panel; Member Conflict: Cognition and Perception.

_Date:_ July 28–29, 2015.
_Time:_ 9:00 a.m. to 5:00 p.m.
_Agenda:_ To review and evaluate grant applications.
_Place:_ National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

_Contact Person:_ Maribeth Champoux, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3176, MSC 7846, Bethesda, MD 20892, 301–594–3163, champoux@csr.nih.gov.

_Name of Committee:_ Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Immunopathology and Immunotherapy.

_Date:_ July 28, 2015.
_Time:_ 1:00 p.m. to 3:00 p.m.
_Agenda:_ To review and evaluate grant applications.
_Place:_ National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

_Contact Person:_ Sharon K Gubancik, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 61950, MSC 7804, Bethesda, MD 20892, (301) 408–9512, gubancim@csr.nih.gov.


_Dated:_ June 26, 2015.

_Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy._

_[FR Doc. 2015–16003 Filed 6–30–15; 8:43 am]_ BILING CODE 4140–01–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Substance Abuse and Mental Health Services Administration**

Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the _Federal Register_ on April 11, 1998 (52 FR 11970), and subsequently revised in the _Federal Register_ on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); and on April 30, 2010 (75 FR 22809).

A notice listing all currently HHS-certified laboratories and IITFs is published in the _Federal Register_ during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://www.samhsa.gov/workplace.

**FOR FURTHER INFORMATION CONTACT:**
Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7–1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276–2610 (fax).

**SUPPLEMENTARY INFORMATION:** The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The "Mandatory Guidelines for Federal Workplace Drug Testing Programs," as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

**HHS-Certified Instrumented Initial Testing Facilities**

Dynacare, 6628 30th Street NW, Edmonton, AB Canada T6B 2N7, 780–784–1190. (Formerly: Gamma-Dynacare Medical Laboratories).

**HHS-Certified Laboratories**


Aegis Analytical Laboratories, Inc., 345 Hill Ave, Nashville, TN 37210, 615–

Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/800–433–3823, [Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.].


Baptist Medical Center-Toxicology Laboratory, 11401 I–30, Little Rock, AR 72206–7006, 501–202–2783, [Formerly: Forensic Toxicology Laboratory Baptist Medical Center].


DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800–235–4890.


Forbes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600, Wilsonville, OR 97070, 503–486–1023.

Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77090, 713–836–8288/800–800–2397.


Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/800–233–6339, [Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center].

LabOne, Inc. d/b/a Quest Diagnostics, 10131 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845, [Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.].


MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950–5295.

Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088.


One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–744–3774, [Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory].

Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–326–6942, [Formerly: Centinela Hospital Airport Toxicology Laboratory].


Phamatext, Inc., 15175 Innovation Drive, San Diego, CA 92126, 888–635–5849.

Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800–729–6432, [Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Beecham Biotechnology Laboratories].

Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800–729–6432, [Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Beecham Biotechnology Laboratories].

Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–8000/677–842–2216, [Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Beecham Biotechnology Laboratories].

Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 91304, 818–737–6370, [Formerly: SmithKline Beecham Clinical Laboratories].

Redwood Toxicology Laboratory, 37000 Redwood Blvd., Santa Rosa, CA 95403, 800–255–2159.


STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington 98421, 800–442–0438.

US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085.

*The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPS) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPS-accredited laboratories was transferred to the U.S. HHS, with the HHS' NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22860). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in the NLCP certification maintenance program.